These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22563515)

  • 21. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.
    Shrestha B; Brien JD; Sukupolvi-Petty S; Austin SK; Edeling MA; Kim T; O'Brien KM; Nelson CA; Johnson S; Fremont DH; Diamond MS
    PLoS Pathog; 2010 Apr; 6(4):e1000823. PubMed ID: 20369024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
    Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
    BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
    Gelanew T; Hunsperger E
    Virol J; 2018 Feb; 15(1):30. PubMed ID: 29409531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency.
    Kotaki T; Kurosu T; Grinyo-Escuer A; Davidson E; Churrotin S; Okabayashi T; Puiprom O; Mulyatno KC; Sucipto TH; Doranz BJ; Ono KI; Soegijanto S; Kameoka M
    Sci Rep; 2021 Jun; 11(1):12987. PubMed ID: 34155267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT; Li PC; Liu IJ; Liao MY; Chiu CY; Chao DY; Wu HC
    PLoS Negl Trop Dis; 2015; 9(7):e0003903. PubMed ID: 26135599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.
    Yamanaka A; Kotaki T; Konishi E
    J Virol; 2013 Dec; 87(23):12828-37. PubMed ID: 24049185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.
    Men R; Yamashiro T; Goncalvez AP; Wernly C; Schofield DJ; Emerson SU; Purcell RH; Lai CJ
    J Virol; 2004 May; 78(9):4665-74. PubMed ID: 15078949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
    Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
    Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The human antibody response to dengue virus infection.
    Wahala WM; Silva AM
    Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.
    Hu D; Zhu Z; Li S; Deng Y; Wu Y; Zhang N; Puri V; Wang C; Zou P; Lei C; Tian X; Wang Y; Zhao Q; Li W; Prabakaran P; Feng Y; Cardosa J; Qin C; Zhou X; Dimitrov DS; Ying T
    PLoS Pathog; 2019 Jun; 15(6):e1007836. PubMed ID: 31242272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
    Messer WB; de Alwis R; Yount BL; Royal SR; Huynh JP; Smith SA; Crowe JE; Doranz BJ; Kahle KM; Pfaff JM; White LJ; Sariol CA; de Silva AM; Baric RS
    Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1939-44. PubMed ID: 24385585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
    Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
    Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.
    Liu L; Wen K; Li J; Hu D; Huang Y; Qiu L; Cai J; Che X
    Clin Vaccine Immunol; 2012 Jan; 19(1):73-8. PubMed ID: 22116689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [To evaluate the neutralizing abilities of anti-dengue virus antibodies with nonstructural protein 1 antigen capture enzyme-linked immunosorbent assay].
    Wen K; Ding YQ; Qiu LW; Pan YX; Cai JP; Yue CF; DI B; Che XY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):680-5. PubMed ID: 20021846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.